A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer

Clinical trial NCT02399137 · COMPLETED

Trial details

NCT number: NCT02399137
Sponsor: Merrimack Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Pancreatic Cancer

Start date: 2015-05-01
Primary completion: 2018-08-01
Enrollment: 88

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.